Table 5 The proposed age-based dosing regimen showing the proportions of individuals who would receive a subtherapeutic, therapeutic or supratherapeutic dose and the corresponding mg base/kg doses of primaquine (PQ)
PQ dose (mg base) | Subtherapeutic dose <0.15 mg/kg, n (%) | Therapeutic dose 0.15–0.5 mg/kg, n (%) | Supratherapeutic dose >0.5 mg/kg, n (%) | Modelled weights by centile (kg) | PQ dose by centile (mg base/kg) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
1st | Median | 99th | 1st | Median | 99th | |||||
0.5 to <1 (n = 39,886) | 1.25 | 10,778 (27.0) | 29,180 (73.2) | 0 | 5.0 | 7.6 | 10.8 | 0.12 | 0.16 | 0.25 |
1–5 (n = 261,036) | 2.5 | 15,744 (6.0) | 244,537 (93.7) | 755 (0.3) | 6.8 | 12.0 | 19.2 | 0.13 | 0.21 | 0.37 |
6–9 (n = 20,770) | 5 | 80 (0.4) | 20,690 (99.6) | 0 | 13.2 | 20.0 | 31.2 | 0.16 | 0.25 | 0.38 |
10–14 (n = 12,155) | 7.5 | 69 (0.6) | 12,086 (99.4) | 0 | 20.0 | 29.0 | 49.0 | 0.15 | 0.26 | 0.38 |
≥15 (n = 328,132) | 15 | 469 (0.14) | 327,620 (99.8) | 43 (0.01) | 37.8 | 55.3 | 90.2 | 0.17 | 0.27 | 0.40 |